Mebentel 100 mg

Mebendazole has attracted cancer-research interest because it acts on microtubules. These structures help both worms and human cells maintain their shape and divide.

Research has investigated whether mebendazole can:

• Disrupt cancer-cell division

• Affect microtubule formation

• Reduce glucose use by cancer cells

• Interfere with abnormal growth signals

• Encourage programmed cancer-cell death

• Reduce the formation of blood vessels around tumours

• Increase the response to certain cancer treatments

Early clinical studies have examined high-dose mebendazole alone or with established treatments in people with brain tumours and gastrointestinal cancers. These studies have mainly assessed safety, tolerability and early signs of activity.

Research continues through laboratory studies, formulation research and clinical investigation. However, there is not enough controlled human evidence to determine whether mebendazole improves survival or controls cancer reliably.

Parasitic worms depend on glucose to produce the energy they need to survive. Mebendazole attaches to a protein called tubulin and prevents the worm from forming normal microtubules.

Without working microtubules, the worm cannot absorb and use glucose properly. Its stored energy gradually runs out, causing it to become immobile and die. The digestive system then removes the dead parasite.

In cancer research, scientists are examining whether similar effects on tubulin and microtubules can interfere with cancer-cell division. Researchers have also reported effects on glucose use, growth signals, blood-vessel formation and programmed cell death in experimental models.

These cancer-related actions have mainly been observed in laboratory, animal and early clinical research. They do not prove that a standard Mebentel 100 mg tablet can treat cancer in people.

There is no single Mebentel dosage suitable for every worm infection. The correct schedule depends on the type of parasite, age, medical history and local treatment guidelines.

For pinworm or threadworm infection, mebendazole is commonly taken as 100 mg once. Another dose can be recommended after two weeks when reinfection occurs or remains likely.

For roundworm, hookworm or whipworm infection, a common schedule is 100 mg in the morning and 100 mg in the evening for three consecutive days.

These are general mebendazole dosing schedules and should not be used to diagnose an infection or select treatment without suitable guidance. Follow the supplied pack instructions or the schedule given by the healthcare professional.

Mebentel can generally be taken with or without food. No special fasting, laxative or restricted diet is normally required. Swallow the tablet with water unless the supplied packaging gives different instructions.

There is no established Mebentel 100 mg dosage for cancer. Cancer studies have used very different doses and combinations under close monitoring. These research schedules should not be copied for self-treatment.

Common Side Effects: Mebentel 100 mg can cause stomach pain, abdominal discomfort, diarrhoea, gas, nausea or vomiting. These effects are usually mild and short-lived. Digestive symptoms can also be connected to the worm infection itself or the body’s response as the parasites die. Contact a healthcare professional if the symptoms become severe or do not settle.

Serious Side Effects: Stop treatment and obtain medical help for facial or throat swelling, breathing difficulty, seizures, a severe blistering rash, yellow skin or eyes, dark urine, unusual bleeding or repeated infections. These symptoms can indicate a serious allergic reaction, liver problem, severe skin reaction or change in blood-cell levels. The risk of severe skin reactions is particularly important when mebendazole is combined with metronidazole.

Mebentel 100 mg requires medical assessment in the following groups:

• People allergic to mebendazole

• People allergic to similar benzimidazoles

• Pregnant women without medical approval

• Children younger than two years

• People with severe liver disease

• People with bone-marrow disorders

• People currently taking metronidazole

• People receiving cancer treatment

• People considering cancer self-treatment

Tell the healthcare professional about all medicines, supplements and herbal products being used.

Important interactions include:

• Metronidazole

• Cimetidine

• Carbamazepine

• Phenytoin

• Other deworming medicines

• Chemotherapy medicines

• Targeted cancer treatments

• Herbal cancer supplements

Combining mebendazole with metronidazole can increase the risk of a serious skin reaction. Cimetidine can increase mebendazole levels, while carbamazepine and phenytoin can reduce its concentration in the body.

Human interaction information for high-dose or long-term cancer use remains limited. Do not combine Mebentel with chemotherapy or another cancer treatment without informing the oncology team.

• Keep Mebentel in its original packaging.

• Follow the storage temperature printed on the pack.

• Store the tablets in a cool and dry place.

• Protect them from direct sunlight and moisture.

• Keep them away from children and pets.

• Do not use tablets from damaged packaging.

• Check the batch number and expiry date before use.

• Dispose of expired tablets according to local requirements.